MedTrace Logo

Clinical Evaluation of VeriSee AMD in Screening for Age-Related Macular Degeneration

NCT05593913 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 986

Last updated 2024-01-22

Study results available
· View outcomes & findings →

Summary

An observational study is designed to evaluate the clinical performance of VeriSee AMD for potential age-related macular degeneration (AMD) screening from color fundus photography images. The sensitivity and specificity of VeriSee AMD's automated image analysis for screening AMD will be determined through the comparison with the gold standard, which is the judgment of AMD by the ophthalmologists.

Conditions

  • Macular Degeneration, Age Related
  • Maculopathy, Age Related

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Acer Medical Inc.

    lead INDUSTRY

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2022-03-03
Completion
2022-08-10

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05593913 on ClinicalTrials.gov